Valuation: Pfizer Inc

Market Cap 14TCr 12TCr 11TCr 10TCr 20TCr 13,19600Cr 20TCr 1,33700Cr 52TCr 6,48000Cr 52TCr 51TCr 22,36300Cr P/E 2026 *
11.4x
P/E 2027 * 12.3x
Enterprise Value 19TCr 16TCr 15TCr 14TCr 27TCr 17,79200Cr 27TCr 1,80200Cr 70TCr 8,73800Cr 70TCr 69TCr 30,15200Cr EV / Sales 2026 *
3.03x
EV / Sales 2027 * 3.05x
Free-Float
59.06%
Yield 2026 *
7.2%
Yield 2027 * 7.17%

Last Transcript: Pfizer Inc

Manager TitleAgeSince
Chief Executive Officer 64 01/01/2019
Director of Finance/CFO 60 02/05/2022
Compliance Officer 65 01/12/2013
Director TitleAgeSince
Director/Board Member 68 01/09/2007
Director/Board Member 62 27/09/2013
Chairman 64 01/01/2020
Change 5-day change 1-year change 3-year change Capi.($)
+1.86%+0.48%+55.50%+163.08% 1,08200Cr
+3.57%+3.29%+68.60%+61.03% 63TCr
+3.99%+3.05%+37.93%+93.37% 46TCr
+3.86%+1.64%+31.35%+24.29% 34TCr
-0.56%+0.96%+41.67%+39.35% 30TCr
-0.08%+1.30%+30.37%+44.02% 29TCr
-1.54%+2.81%-25.35%-39.61% 22TCr
+3.55%+4.41%+25.45%+66.28% 20TCr
+4.21%+2.65%+17.47%+71.11% 16TCr
Average +2.10%+4.58%+31.44%+58.10% 41.03TCr
Weighted average by Cap. +2.25%+5.53%+42.06%+83.22%

Financials

2026 *2027 *
Net sales 6.17TCr 5.4TCr 4.95TCr 4.62TCr 8.76TCr 5,87300Cr 8.89TCr 59TCr 23TCr 2,88400Cr 23TCr 23TCr 9,95300Cr 5.93TCr 5.19TCr 4.76TCr 4.45TCr 8.42TCr 5,64800Cr 8.55TCr 57TCr 22TCr 2,77400Cr 22TCr 22TCr 9,57100Cr
Net income 1.11TCr 968.17Cr 888.58Cr 829.48Cr 1.57TCr 1,05400Cr 1.6TCr 11TCr 4.15TCr 52TCr 4.16TCr 4.07TCr 1,78600Cr 1.07TCr 937.26Cr 860.21Cr 803Cr 1.52TCr 1,02000Cr 1.54TCr 10TCr 4.02TCr 50TCr 4.02TCr 3.94TCr 1,72900Cr
Net Debt 4.83TCr 4.22TCr 3.88TCr 3.62TCr 6.85TCr 4,59600Cr 6.96TCr 47TCr 18TCr 2,25700Cr 18TCr 18TCr 7,78900Cr 4.21TCr 3.68TCr 3.38TCr 3.15TCr 5.97TCr 4,00600Cr 6.06TCr 41TCr 16TCr 1,96700Cr 16TCr 15TCr 6,78800Cr
Logo Pfizer Inc
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (47.4%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (26.2%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (24.5%); - other (1.9%). The United States accounts for 60.8% of net sales.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-